← back to search

Walter Reinisch

Pädagogische Hochschule Wien · AT
Area of research
Genetics · Epidemiology
Research interest
Research interests include Inflammatory Bowel Disease, Microscopic Colitis, Autoimmune and Inflammatory Disorders, and Rheumatoid Arthritis Research and Therapies.
h-index
44
citations
16,438
works
133
NIH funding
primary concept
Medicine
email

Recent publications

INSPECT: A Retrospective Study to Evaluate Long-term Effectiveness and Safety of Darvadstrocel in Patients With Perianal Fistulizing Crohn’s Disease Treated in the ADMIRE-CD Trial
Inflammatory Bowel Diseases 2022cited by 57position: middledoi
IOIBD Recommendations for Clinical Trials in Ulcerative Proctitis: The PROCTRIAL Consensus
Clinical Gastroenterology and Hepatology 2022cited by 20position: middledoi
Deep Remission at 1 Year Prevents Progression of Early Crohn’s Disease
Gastroenterology 2020cited by 233position: middledoi
Approaches to Integrating Biomarkers Into Clinical Trials and Care Pathways as Targets for the Treatment of Inflammatory Bowel Diseases
Gastroenterology 2019cited by 58position: middledoi
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial
The Lancet 2017cited by 904position: middledoi
Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn’s Disease
Gastroenterology 2017cited by 480position: middledoi
Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection
Gastroenterology 2016cited by 326position: middledoi
Development of an index to define overall disease severity in IBD
Gut 2016cited by 150position: middledoi
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
The American Journal of Gastroenterology 2015cited by 1,820position: middledoi
Clinical Practice Guidelines for the Medical Management of Nonhospitalized Ulcerative Colitis: The Toronto Consensus
Gastroenterology 2015cited by 410position: middledoi
Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease – a <scp>SONIC </scp><i>post hoc</i> analysis
Alimentary Pharmacology & Therapeutics 2015cited by 190position: middledoi
Briakinumab for Treatment of Crohnʼs Disease
Inflammatory Bowel Diseases 2015cited by 76position: middledoi
Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study
Journal of Crohn s and Colitis 2015cited by 74position: middledoi
The Impact of Clinical Information on the Assessment of Endoscopic Activity: Characteristics of the Ulcerative Colitis Endoscopic Index Of Severity [UCEIS]
Journal of Crohn s and Colitis 2015cited by 59position: middledoi
Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines
Journal of Crohn s and Colitis 2013cited by 659position: middledoi
Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial
Gut 2013cited by 490position: middledoi
Reliability and Initial Validation of the Ulcerative Colitis Endoscopic Index of Severity
Gastroenterology 2013cited by 443position: middledoi
Review article: the role of anti‐TNF in the management of ulcerative colitis – past, present and future
Alimentary Pharmacology & Therapeutics 2013cited by 91position: lastdoi
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
Gut 2012cited by 1,482position: middledoi
Development of the Paris Definition of Early Crohn's Disease for Disease-Modification Trials: Results of an International Expert Opinion Process
The American Journal of Gastroenterology 2012cited by 109position: middledoi
Challenges to the Design, Execution, and Analysis of Randomized Controlled Trials for Inflammatory Bowel Disease
Gastroenterology 2012cited by 54position: middledoi
Results of the 2nd scientific workshop of the ECCO (IV): Therapeutic strategies to enhance intestinal healing in inflammatory bowel disease
Journal of Crohn s and Colitis 2012cited by 46position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

William J. Sandborn · Mirati Therapeutics (United States)9 papers (2012–2019)Brian G. Feagan · Western University7 papers (2012–2015)Bruce E. Sands · Seattle University5 papers (2012–2019)Laurent Peyrin‐Biroulet · Hôpital Lapeyronie5 papers (2012–2019)Jean‐Frédéric Colombel · Cornell University4 papers (2012–2015)Silvio Danese · Io Therapeutics (United States)4 papers (2012–2019)Simon Travis · University of Oxford4 papers (2012–2015)Remo Panaccione · Nutrition-Génétique et Exposition aux Risques Environnementaux3 papers (2012–2015)Stephen B. Hanauer · Northwestern University3 papers (2013–2015)Gerassimos J. Mantzaris · Polyclinic General Hospital3 papers (2013–2019)Geert D’Haens · Vrije Universiteit Amsterdam3 papers (2012–2012)Paul Rutgeerts · KU Leuven3 papers (2012–2013)Jean–Frédéric Colombel · University Hospital Medical Center Bezanijska kosa3 papers (2012–2013) · 2 papers (2013–2015) · 2 papers (2012–2013) · 2 papers (2015–2019)Gary R. Lichtenstein · Penn Center for AIDS Research2 papers (2013–2015)María T. Abreu · Umeå University2 papers (2013–2015)Philippe Marteau · Drexel University2 papers (2013–2015) · 2 papers (2013–2015)